[Towards gene therapy in familial hypercholesterolemia]

Area of Science:

• Genetics and Molecular Biology
• Hepatology
• Gene Therapy

Context:

• Familial hypercholesterolemia (FH) is a genetic disorder characterized by defects in the Low Density Lipoprotein receptor (LDL-R) gene.
• Current gene therapy research focuses on improving transduction efficiency and long-term gene expression for FH treatment.
• In vivo hepatic gene therapy aims to restore normal LDL-R protein expression in hepatocytes to correct the disease.

Purpose:

• To develop an efficient and reliable method for in vivo transduction of primary hepatocytes.
• To create a retroviral vector for high and tissue-specific expression of LDL-R cDNA in hepatocytes.
• To investigate the potential of gene therapy for correcting LDL-R deficiency in familial hypercholesterolemia.

Summary:

• A retroviral vector utilizing the liver-type pyruvate kinase promoter was developed for efficient in vivo transduction of human, mouse, and primate primary hepatocytes.
• This vector drives high and tissue-specific expression of the Low Density Lipoprotein receptor (LDL-R) cDNA.
• A secondary vector with a housekeeping promoter was designed to correct LDL-R deficiency in fibroblasts from familial hypercholesterolemia patients.

Impact:

• This research offers a new therapeutic strategy for familial hypercholesterolemia by enabling efficient gene correction in liver cells.
• Preclinical studies in non-human primates will offer insights into the biology of transduced cells post-reimplantation.
• The developed method holds potential for advancing gene therapy applications in inherited metabolic diseases.